| |
WHO Updates Gudelines: recommends Treatment
at any CD4 & PrEP; IDSA Commends
|
| |
| |
Download the PDF here
This morning, the World Health Organization (WHO) released an updated guideline on when to start ART and PrEP for HIV. The guideline recommends that countries offer life-saving treatment to all people with the virus, including the preventive use of tenofovir.
The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) support this important step toward controlling the HIV pandemic. Please see below for an IDSA and HIVMA Center for Global Health Policy statement from Global Center co-chair Dr. Ken Mayer.
Center for Global Health Policy commends WHO on release of Guideline on HIV Treatment for all and Pre-Exposure Prophylaxis Initiation
Statement from Ken Mayer, MD, co-chair of Scientific Advisory Committee
The World Health Organization's updated guideline on when to start ART and PrEP for HIV reflects realities and research showing all of the benefits offered by access to antiretroviral drugs. The guidelines recognize that antiretroviral treatment access upon diagnosis saves lives, averts serious illnesses, and prevents new infections, and that access to the treatment as pre-exposure prophylaxis can protect those at substantial risk of becoming infected. As physicians and researchers witnessing the impact of HIV globally, and working to stem its toll, we applaud WHO for taking an important step toward control of the HIV pandemic by recommending that countries offer life-saving treatment to all people with the virus and preventive use of tenofovir.
We encourage U.S. policy makers and other world leaders to support these evidence-based recommendations by adding the resources necessary for countries to adopt the standard of care already practiced in the United States.
|
|
| |
| |
|
|
|
